the company has clear direction. They complete the studies as required by the FDA and sell Roxan early 26 while they wait.
They don't control what the FDA want they react and clearly had a back up plan. Will be interesting to hear the new timeline tomorrow and further details.
Big pharma didn't pursue because they couldn't stop it from crystallizing in the bottle amongst other things.
LTP Price at posting:
45.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)